NCT03234738View on ClinicalTrials.gov

A Phase 1 Safety and PK Study of IV TP-271

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

January 2, 2018

Study Completion Date

January 2, 2018

Conditions
Bacterial Infections
Interventions
DRUG

TP-271

multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

DRUG

Placebo

Placebo is sterile 0.45% saline randomized 3:1 to receive

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Tetraphase Pharmaceuticals, Inc

INDUSTRY

NCT03234738 - A Phase 1 Safety and PK Study of IV TP-271 | Biotech Hunter | Biotech Hunter